A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines

Kongming Wu, Mark D'Amico, Chenguang Wang, Chris Albanese, Richard G. Pestell, Sridhar Mani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Flavopiridol and UCN-01 are two novel protein kinase inhibitors with diverse cellular effects that may complement each other with regards to induction of apoptosis. HeLa cells engineered to overexpress human survivin (HeLa-S) were at least ∼4.8-fold resistant to UCN-01 relative to proliferation observed in control HeLa cells (HeLa-V). Flavopiridol cytotoxicity as measured using the MTT assay was unaffected in HeLa-S cells when compared with HeLa-V cells. Similarly, simultaneous treatment of HeLa-V cells with flavopiridol and UCN-01 for 72 hours did not result in synergistic inhibition of proliferation; however, in HeLa-S cells, this combination resulted in synergistic inhibition of cell proliferation. Flavopiridol and UCN-01 augmented apoptosis in HeLa-S cells (as compared with HeLa-V cells) as measured by caspase-3 cellular activity assay, DNA fragmentation and PARP cleavage by western blot. In HeLa-V and -S cells, combination treatment resulted in caspase-8 cleavage. Caspase-9 was expressed in HeLa-V cells; however, there was a marked reduction of caspase-9 content in HeLa-S cells only. Combination treatment resulted in a significant reduction in survivin abundance in HeLa-S and SKBR3-UR cells, but not in their respective parental lines. The synergy of Flavopiridol and UCN-01 are selectively toxic to survivin-overexpressing cell lines and the mechanism of toxicity involves caspase-dependent cell death.

Original languageEnglish (US)
Pages (from-to)299-309
Number of pages11
JournalInvestigational New Drugs
Volume23
Issue number4
DOIs
StatePublished - Aug 2005

Fingerprint

alvocidib
HeLa Cells
Cell Line
Caspase 9
7-hydroxystaurosporine
Apoptosis
Caspase 8

Keywords

  • Caspases
  • Flavopiridol
  • HeLa cells
  • IAP
  • Survivin
  • UCN-01

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. / Wu, Kongming; D'Amico, Mark; Wang, Chenguang; Albanese, Chris; Pestell, Richard G.; Mani, Sridhar.

In: Investigational New Drugs, Vol. 23, No. 4, 08.2005, p. 299-309.

Research output: Contribution to journalArticle

Wu, Kongming ; D'Amico, Mark ; Wang, Chenguang ; Albanese, Chris ; Pestell, Richard G. ; Mani, Sridhar. / A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. In: Investigational New Drugs. 2005 ; Vol. 23, No. 4. pp. 299-309.
@article{6f503fd79d344bc4b93793e58115349e,
title = "A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines",
abstract = "Flavopiridol and UCN-01 are two novel protein kinase inhibitors with diverse cellular effects that may complement each other with regards to induction of apoptosis. HeLa cells engineered to overexpress human survivin (HeLa-S) were at least ∼4.8-fold resistant to UCN-01 relative to proliferation observed in control HeLa cells (HeLa-V). Flavopiridol cytotoxicity as measured using the MTT assay was unaffected in HeLa-S cells when compared with HeLa-V cells. Similarly, simultaneous treatment of HeLa-V cells with flavopiridol and UCN-01 for 72 hours did not result in synergistic inhibition of proliferation; however, in HeLa-S cells, this combination resulted in synergistic inhibition of cell proliferation. Flavopiridol and UCN-01 augmented apoptosis in HeLa-S cells (as compared with HeLa-V cells) as measured by caspase-3 cellular activity assay, DNA fragmentation and PARP cleavage by western blot. In HeLa-V and -S cells, combination treatment resulted in caspase-8 cleavage. Caspase-9 was expressed in HeLa-V cells; however, there was a marked reduction of caspase-9 content in HeLa-S cells only. Combination treatment resulted in a significant reduction in survivin abundance in HeLa-S and SKBR3-UR cells, but not in their respective parental lines. The synergy of Flavopiridol and UCN-01 are selectively toxic to survivin-overexpressing cell lines and the mechanism of toxicity involves caspase-dependent cell death.",
keywords = "Caspases, Flavopiridol, HeLa cells, IAP, Survivin, UCN-01",
author = "Kongming Wu and Mark D'Amico and Chenguang Wang and Chris Albanese and Pestell, {Richard G.} and Sridhar Mani",
year = "2005",
month = "8",
doi = "10.1007/s10637-005-1438-y",
language = "English (US)",
volume = "23",
pages = "299--309",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines

AU - Wu, Kongming

AU - D'Amico, Mark

AU - Wang, Chenguang

AU - Albanese, Chris

AU - Pestell, Richard G.

AU - Mani, Sridhar

PY - 2005/8

Y1 - 2005/8

N2 - Flavopiridol and UCN-01 are two novel protein kinase inhibitors with diverse cellular effects that may complement each other with regards to induction of apoptosis. HeLa cells engineered to overexpress human survivin (HeLa-S) were at least ∼4.8-fold resistant to UCN-01 relative to proliferation observed in control HeLa cells (HeLa-V). Flavopiridol cytotoxicity as measured using the MTT assay was unaffected in HeLa-S cells when compared with HeLa-V cells. Similarly, simultaneous treatment of HeLa-V cells with flavopiridol and UCN-01 for 72 hours did not result in synergistic inhibition of proliferation; however, in HeLa-S cells, this combination resulted in synergistic inhibition of cell proliferation. Flavopiridol and UCN-01 augmented apoptosis in HeLa-S cells (as compared with HeLa-V cells) as measured by caspase-3 cellular activity assay, DNA fragmentation and PARP cleavage by western blot. In HeLa-V and -S cells, combination treatment resulted in caspase-8 cleavage. Caspase-9 was expressed in HeLa-V cells; however, there was a marked reduction of caspase-9 content in HeLa-S cells only. Combination treatment resulted in a significant reduction in survivin abundance in HeLa-S and SKBR3-UR cells, but not in their respective parental lines. The synergy of Flavopiridol and UCN-01 are selectively toxic to survivin-overexpressing cell lines and the mechanism of toxicity involves caspase-dependent cell death.

AB - Flavopiridol and UCN-01 are two novel protein kinase inhibitors with diverse cellular effects that may complement each other with regards to induction of apoptosis. HeLa cells engineered to overexpress human survivin (HeLa-S) were at least ∼4.8-fold resistant to UCN-01 relative to proliferation observed in control HeLa cells (HeLa-V). Flavopiridol cytotoxicity as measured using the MTT assay was unaffected in HeLa-S cells when compared with HeLa-V cells. Similarly, simultaneous treatment of HeLa-V cells with flavopiridol and UCN-01 for 72 hours did not result in synergistic inhibition of proliferation; however, in HeLa-S cells, this combination resulted in synergistic inhibition of cell proliferation. Flavopiridol and UCN-01 augmented apoptosis in HeLa-S cells (as compared with HeLa-V cells) as measured by caspase-3 cellular activity assay, DNA fragmentation and PARP cleavage by western blot. In HeLa-V and -S cells, combination treatment resulted in caspase-8 cleavage. Caspase-9 was expressed in HeLa-V cells; however, there was a marked reduction of caspase-9 content in HeLa-S cells only. Combination treatment resulted in a significant reduction in survivin abundance in HeLa-S and SKBR3-UR cells, but not in their respective parental lines. The synergy of Flavopiridol and UCN-01 are selectively toxic to survivin-overexpressing cell lines and the mechanism of toxicity involves caspase-dependent cell death.

KW - Caspases

KW - Flavopiridol

KW - HeLa cells

KW - IAP

KW - Survivin

KW - UCN-01

UR - http://www.scopus.com/inward/record.url?scp=22144460455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144460455&partnerID=8YFLogxK

U2 - 10.1007/s10637-005-1438-y

DO - 10.1007/s10637-005-1438-y

M3 - Article

VL - 23

SP - 299

EP - 309

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -